MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie.

Antimicrobial Agents and Chemotherapy
Karim Tarik AdjouD Dormont

Abstract

To test the efficacy of a new amphotericin B derivative, MS-8209, in delaying scrapie, hamsters were infected intracerebrally with the 263K scrapie agent and treated with MS-8209 either early in the course of the disease or continuously. The results show that (i) all treatments lengthened the incubation period of hamster scrapie, (ii) continuous treatment with MS-8209 doubled the length of the incubation period compared with that observed in infected, untreated animals, and (iii) all treatments delayed the accumulation of a proteinase-resistant prion protein and glial fibrillary acidic protein in the brain. These findings suggest that MS-8209 is a powerful tool for investigating the pathogenesis of transmissible subacute spongiform encephalopathies.

References

Mar 1, 1992·The Journal of General Virology·A LadoganaM Pocchiari
Dec 1, 1992·Antimicrobial Agents and Chemotherapy·L Saint-JulienP Yeni
Jan 1, 1987·The Journal of General Virology·M PocchiariC Masullo
Nov 1, 1989·The Journal of Infectious Diseases·M PocchiariA Ladogana
Aug 1, 1984·The Journal of General Virology·B Ehlers, H Diringer
Jan 1, 1983·Annual Review of Pharmacology and Toxicology·G MedoffJ Bolard
Dec 24, 1982·Science·D C BoltonS B Prusiner
Jan 1, 1995·Journal of Virology·L IngrossoM Pocchiari

❮ Previous
Next ❯

Citations

Oct 14, 2009·Cellular and Molecular Life Sciences : CMLS·Sabine GilchHermann M Schätzl
Dec 8, 2006·Cellular and Molecular Neurobiology·Karen VanaStefan Weiss
Sep 21, 2000·Mechanisms of Ageing and Development·W E MüllerH C Schröder
Sep 12, 2002·International Journal of Food Microbiology·Dominique Dormont
Dec 16, 1998·Research in Immunology·D Dormont
Aug 1, 2002·Proceedings of the National Academy of Sciences of the United States of America·Gianluigi ForloniFabrizio Tagliavini
Aug 7, 2007·Expert Review of Anti-infective Therapy·Heike LudewigsStefan Weiss
Jan 24, 2003·Expert Opinion on Therapeutic Targets·Mark W HeadJanet R Fraser
Nov 25, 2014·Viruses·Samia HannaouiSabine Gilch
Jun 14, 2008·Expert Opinion on Biological Therapy·Sabine GilchHermann M Schätzl
Apr 1, 1997·Expert Opinion on Investigational Drugs·V BeringueD Dormont
Apr 30, 2008·Neurochemistry International·Karim Tarik AdjouMichel Seman
May 8, 2003·Clinics in Laboratory Medicine·Giacomina RossiFabrizio Tagliavini
Dec 20, 2007·The Journal of General Virology·M-P CourageotD Vilette
Jul 1, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·C Rogez-KreuzP Clayette
Oct 3, 2003·British Medical Bulletin·Dominique Dormont
Feb 24, 2001·Nature·C Thompson
Aug 15, 2003·The Journal of General Virology·Karim Tarik AdjouCorinne Ida Lasmézas
Jul 25, 2000·Journal of Molecular Biology·F TagliaviniM Salmona
May 27, 2016·Clinical Microbiology Reviews·Alvin S Das, Wen-Quan Zou

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.